Investigation of PON1 activity and MDA levels in patients with epilepsy not receiving antiepileptic treatment

Basit Öğe Kaydı
dc.contributor.authorDonmezdil, Nilufer
dc.contributor.authorCevik, Mehmet Ugur
dc.contributor.authorOzdemir, Hasan Huseyin
dc.contributor.authorTasin, Muhterem
dc.date.accessioned2024-04-24T17:18:28Z
dc.date.available2024-04-24T17:18:28Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: There are many studies dedicated to researching the etiopathogenesis of epilepsy. In such research, oxidative and antioxidant indicators of etiopathogenesis have also been examined under the scope. Drawing on a group of patients with epilepsy who were receiving no treatment, we have tried to evaluate whether or not an increase in oxidative indicators is linked directly with the disorder, independent of epileptic medicaments. Methods: Thirty people in good health and 30 newly diagnosed with epilepsy and who received ambulatory treatment in the polyclinic of the Neurology Department took part in the study. The tests relating to serum malondialdehyde (MDA) levels and paraoxonase 1 (PON1) activity were carried out in the biochemistry laboratory. Results: Even though the levels of MDA in the patient group (14.34 +/- 3.59 nmol/mL) were found to be high compared to those of the control group, which consisted of people in good health (13.53 +/- 3.56 nmol/mL), there was no statistically significant difference. PON1 activity in the serum taken from people in the patient group (0.65 +/- 0.17) was lower in comparison to that observed in the serum of the control group (0.71 +/- 0.17 U/L). Nonetheless, it was not so low as to have significance from a statistical point of view. Conclusion: We conclude that such a high level of oxidative parameters should have been related to the disease and that statistically significant findings that emerged in some other studies could have been related to an antiepileptic treatment.en_US
dc.identifier.doi10.2147/NDT.S103336
dc.identifier.endpage1017en_US
dc.identifier.issn1178-2021
dc.identifier.pmid27175078
dc.identifier.scopus2-s2.0-84968611376
dc.identifier.scopusqualityQ2
dc.identifier.startpage1013en_US
dc.identifier.urihttps://doi.org/10.2147/NDT.S103336
dc.identifier.urihttps://hdl.handle.net/11468/18791
dc.identifier.volume12en_US
dc.identifier.wosWOS:000374743600001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherDove Medical Press Ltden_US
dc.relation.ispartofNeuropsychiatric Disease and Treatment
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEpilepsyen_US
dc.subjectParaoxonase 1en_US
dc.subjectMalondialdehydeen_US
dc.subjectOxidative Stressen_US
dc.subjectEpilepsyen_US
dc.subjectBiochemical Markeren_US
dc.titleInvestigation of PON1 activity and MDA levels in patients with epilepsy not receiving antiepileptic treatmenten_US
dc.titleInvestigation of PON1 activity and MDA levels in patients with epilepsy not receiving antiepileptic treatment
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu